Metraipolis › archive › dc_48bed82ff3af

Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes — Europe PMC PMID:41190032

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41190032
DOI
10.3389/fphar.2025.1686851
License (as archived)
solo-consultazione
Archived
2026-11-09T05:10:00.240Z
SHA-256 of the archived text
789e53c9c63bf1d3e620ac9164f52ea7e7ed2b446d9ebb1c87cba4792fb873b3
Stable URL of this page
https://metraipolis.com/documento/dc_48bed82ff3af

How to cite

Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes — Europe PMC PMID:41190032 — Europe PMC (en), https://europepmc.org/article/MED/41190032 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_48bed82ff3af (Metraipolis archive dc_48bed82ff3af, sha256 789e53c9c63bf1d3e620ac9164f52ea7e7ed2b446d9ebb1c87cba4792fb873b3)
BibTeX
@misc{dc48bed82ff3af,
  title = {Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes — Europe PMC PMID:41190032},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41190032},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_48bed82ff3af; sha256 789e53c9c63bf1d3e620ac9164f52ea7e7ed2b446d9ebb1c87cba4792fb873b3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41190032. Agents can read the archived copy with the MCP tool read_document.